Compare FEAM & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEAM | CLNN |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | 35 | 76 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 69.7M |
| IPO Year | N/A | N/A |
| Metric | FEAM | CLNN |
|---|---|---|
| Price | $1.24 | $4.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.38 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 226.7K | 72.1K |
| Earning Date | 05-14-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.20 |
| Revenue Next Year | N/A | $20,465.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.25 | $2.28 |
| 52 Week High | $7.50 | $13.50 |
| Indicator | FEAM | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 26.37 | 45.53 |
| Support Level | N/A | $3.54 |
| Resistance Level | $2.16 | $6.83 |
| Average True Range (ATR) | 0.16 | 0.63 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 4.71 | 21.66 |
5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.